Charles Bisgaier
Directeur Général chez Genetobe LLC
Profil
Charles Bisgaier is the founder of Genetobe LLC.
He currently works as a Director at Diapin Therapeutics LLC.
Postes actifs de Charles Bisgaier
| Sociétés | Poste | Début |
|---|---|---|
Diapin Therapeutics LLC
 Diapin Therapeutics LLC BiotechnologyHealth Technology Diapin Therapeutics LLC operates as a pre-seed, preclinical development-staged company .The company was founded by Yuqing Chen in 2011 and is headquartered in Ann Arbor, MI. | Directeur/Membre du Conseil | - |
Genetobe LLC
 Genetobe LLC Packaged SoftwareTechnology Services Genetobe LLC is a genetic disease company based in Ann Arbor, MI, USA. The company's mission is to create translational genetic disease models for demonstrating preclinical efficacy. The company has preclinical and clinical stage assets with proof of concept in preclinical in vivo models. Genetobe uses a next-generation CRISPR/Cas9 platform for their technology. The management team has over 150 years of experience in drug discovery, development, registration, and commercialization that has produced multiple registered pharmaceutical products and candidates. The company was founded by Charles Bisgaier and Eugene Chen, and Charles Bisgaier has been the CEO since incorporation. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Diapin Therapeutics LLC
Diapin Therapeutics LLC BiotechnologyHealth Technology Diapin Therapeutics LLC operates as a pre-seed, preclinical development-staged company .The company was founded by Yuqing Chen in 2011 and is headquartered in Ann Arbor, MI. | Health Technology |
Genetobe LLC
Genetobe LLC Packaged SoftwareTechnology Services Genetobe LLC is a genetic disease company based in Ann Arbor, MI, USA. The company's mission is to create translational genetic disease models for demonstrating preclinical efficacy. The company has preclinical and clinical stage assets with proof of concept in preclinical in vivo models. Genetobe uses a next-generation CRISPR/Cas9 platform for their technology. The management team has over 150 years of experience in drug discovery, development, registration, and commercialization that has produced multiple registered pharmaceutical products and candidates. The company was founded by Charles Bisgaier and Eugene Chen, and Charles Bisgaier has been the CEO since incorporation. | Technology Services |
